Integra LifeSciences, a global medical technology company, completed the acquisition of ACell, an innovative regenerative medicine company, for $400m. "ACell expands our regenerative capabilities and is complementary to Integra's existing tissue technologies portfolio. The porcine UBM technology is a strong strategic fit with our human amniotic tissue and bovine-derived engineered collagen and acellular dermal matrices. The acquisition also supports our long-term growth and profitability strategy with a financial profile similar to Integra’s tissue products," Peter Arduini, Integra LifeSciences President and CEO.